{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:07:37Z","timestamp":1784977657321,"version":"3.55.0"},"reference-count":93,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bruton\u2019s tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for patients with indolent lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The most common adverse events include cardiac arrhythmia, bleeding, infection, diarrhea, arthralgias, hypertension, and skin changes. Second-generation BTK inhibitors, e.g., acalabrutinib and zanubrutinib and the non-covalent BTK inhibitor pirtobrutinib, are less toxic than the first-generation BTK inhibitor ibrutinib. The most common toxic skin symptoms related to BTKi treatment include hemorrhage, bleeding events, bruising, skin ecchymoses, and contusion; they are particularly common in patients treated with ibrutinib. Other dermatologic symptoms include rash, cellulitis, skin infections, subcutaneous abscesses and peripheral edema. This article discusses the development of skin symptoms in patients with ibrutinib and newer BTK inhibitors, and summarizes their clinical and pathological characteristics. A literature search was performed using PubMed, Web of Science, and Google Scholar for articles published in English. Additional relevant publications were obtained by reviewing the references from the chosen articles.<\/jats:p>","DOI":"10.3390\/cancers18030371","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T11:14:07Z","timestamp":1769426047000},"page":"371","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4633-9160","authenticated-orcid":false,"given":"Ewa","family":"Robak","sequence":"first","affiliation":[{"name":"Department of Dermatology, Medical University of Lodz, 90-647 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland"},{"name":"Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital, 93-510 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Robak, T., Iskierka-Ja\u017cd\u017cewska, E., Pu\u0142a, A., Robak, P., and Pu\u0142a, B. (2025). The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs. J. Clin. Med., 14.","DOI":"10.3390\/jcm14228247"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: Drug development advances","volume":"35","author":"Wen","year":"2020","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Robak, T., Witkowska, M., and Smolewski, P. (2022). The Role of Bruton\u2019s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. Cancers, 14.","DOI":"10.3390\/cancers14030771"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-022-01764-1","article-title":"A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas","volume":"37","author":"Falini","year":"2022","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Robak, E., and Robak, T. (2022). Bruton\u2019s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. J. Clin. Med., 11.","DOI":"10.37247\/PAMED4ED.4.22.14"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2024.2410003","article-title":"BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: Current treatments and overcoming resistance","volume":"17","author":"Robak","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"ref_7","first-page":"62","article-title":"Pirtobrutinib preclinical characterization: A highly selective, non-covalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Woyach, J.A., Qiu, L., Grosicki, S., Wrobel, T., Capra, M., Czyz, J., Yi, S., Eom, K.S., Panovsk\u00e1, A., and Jurczak, W. (2025). Pirtobrutinib Versus Ibrutinib in Treatment-Na\u00efve and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. J. Clin. Oncol., JCO2502477.","DOI":"10.1200\/JCO-25-02477"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"O\u2019brien, S.M., Brown, J.R., Byrd, J.C., Furman, R.R., Ghia, P., Sharman, J.P., and Wierda, W.G. (2021). Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.720704"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological Toxicities of Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2023.03.010","article-title":"Treatment Discontinuation Patterns for Patients with Chronic Lymphocytic Leukemia in Real-World Settings: Results from a Multi-Center International Study","volume":"23","author":"Shadman","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/blood-2019-130062","article-title":"Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients","volume":"134","author":"Yazdy","year":"2019","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jaad.2023.03.048","article-title":"Cutaneous adverse reactions to Bruton tyrosine kinase inhibitors: Banal to brutal","volume":"88","author":"Heymann","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jaad.2019.12.031","article-title":"Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor\u2013induced dermatologic adverse events","volume":"88","author":"Singer","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wang, L., Tang, J., Feng, J., Huang, Y., Cheng, Y., Xu, H., and Miao, Y. (2022). Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.941633"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Estupi\u00f1\u00e1n, H.Y., Bergl\u00f6f, A., Zain, R., and Smith, C.I.E. (2021). Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.630942"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103696","DOI":"10.1016\/j.critrevonc.2022.103696","article-title":"Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis","volume":"174","author":"Nocco","year":"2022","journal-title":"Crit. Rev. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis","volume":"184","author":"Brown","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/14740338.2024.2339448","article-title":"Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS)","volume":"24","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: Pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of Major Bleeding with Ibrutinib","volume":"18","author":"Mock","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_30","first-page":"100067","article-title":"Imbruvica (Ibrutinib) induced subcutaneous hematoma: A case report","volume":"3","author":"Jani","year":"2021","journal-title":"Curr. Probl. Cancer Case Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.18995","article-title":"Bleeding risk with concurrent use of anticoagulants and ibrutinib: A population-based nested case-control study","volume":"203","author":"Allouchery","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"von Hundelshausen, P., and Siess, W. (2021). Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. Cancers, 13.","DOI":"10.3390\/cancers13051103"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies","volume":"35","author":"Furman","year":"2021","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jdcr.2024.01.020","article-title":"Zanubrutinib-induced petechial ecchymotic reaction in a previously irradiated area in a patient with chronic lymphocytic leukemia","volume":"46","author":"Vilasi","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhou, J., Ma, W., Hu, N., Ma, Y., Zhu, H., and Gao, L. (2024). Severe atypical skin disease in two patients with CLL\/SLL after BTKi treatment\u2014A case report and literature review. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1467891"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jha2.1013","article-title":"Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy","volume":"5","author":"Lamanna","year":"2024","journal-title":"eJHaem"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1016\/S2352-3026(24)00213-8","article-title":"Zanubrutinib-associated ecchymotic lesions","volume":"11","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_38","first-page":"e92366","article-title":"Zanubrutinib-Induced Symmetrical Soft Tissue Forearm Swelling in a Patient With Waldenstr\u00f6m Macroglobulinemia","volume":"17","author":"Samperio","year":"2025","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jdcr.2024.06.011","article-title":"Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton\u2019s tyrosine kinase inhibitor","volume":"51","author":"Kucharik","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_40","first-page":"313","article-title":"Extensive ecchymotic patch in a patient with chronic lymphocytic leukemia","volume":"63","author":"Guenther","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.1111\/ajd.13787","article-title":"A uniquely distributed purpuric drug eruption from acalabrutinib","volume":"63","author":"Truong","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamaoncol.2015.0457","article-title":"Panniculitis in Patients Undergoing Treatment with the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias","volume":"1","author":"Fabbro","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.14302","article-title":"Ibrutinib-associated rash: A single-centre experience of clinicopathological features and management","volume":"180","author":"Iberri","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4274\/tjh.galenos.2020.2020.0120","article-title":"Ibrutinib-Induced Skin Rash","volume":"38","author":"Kirar","year":"2021","journal-title":"Turk. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1093\/ajcp\/aqad150.057","article-title":"Acalabrutinib-Related Dermal Toxicities: A Next-Generation Diagnostic Challenge","volume":"160","author":"Portillo","year":"2023","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.4081\/dr.2017.6976","article-title":"Ibrutinib-associated skin toxicity: A case of maculopapular rash in a 79-year old Caucasian male patient with relapsed Waldenstrom\u2019s macroglobulinemia and review of the literature","volume":"9","author":"Jensen","year":"2017","journal-title":"Dermatol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit. Rev. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11899-020-00576-3","article-title":"Management of Ibrutinib Toxicities: A Practical Guide","volume":"15","author":"Lasica","year":"2020","journal-title":"Curr. Hematol. Malign. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jdcr.2017.06.035","article-title":"Ibrutinib-associated pityriasis rosea\u2013like rash","volume":"4","author":"Bitar","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ad.2023.04.039","article-title":"Cutaneous Lymphocytic Vasculitis Due to Ibrutinib Therapy","volume":"115","year":"2024","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/ajh.25597","article-title":"A rash in a hairy situation: Leukocytoclastic vasculitis at presentation of hairy cell Leukemia","volume":"94","author":"Moyers","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"106571","DOI":"10.1016\/j.leukres.2021.106571","article-title":"Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab","volume":"104","author":"Robak","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23775","article-title":"Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia","volume":"90","author":"Mannis","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4274\/tjh.galenos.2023.2023.0368","article-title":"Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia","volume":"41","author":"Kaya","year":"2024","journal-title":"Turk. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.abd.2020.07.023","article-title":"Neutrophilic dermatosis of the dorsal hands related to cocaine abuse","volume":"96","year":"2021","journal-title":"An. Bras. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-2-34","article-title":"Sweet\u2019s syndrome\u2014A comprehensive review of an acute febrile neutrophilic dermatosis","volume":"2","author":"Cohen","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"bcr2016217606","DOI":"10.1136\/bcr-2016-217606","article-title":"Sweet syndrome: A painful reality","volume":"2016","author":"Khan","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jdcr.2017.01.027","article-title":"Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia","volume":"3","author":"Hammel","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/DAD.0000000000000862","article-title":"Ibrutinib-Induced Neutrophilic Dermatosis","volume":"40","author":"Michot","year":"2018","journal-title":"Am. J. Dermatopathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ijd.17968","article-title":"Atypical Neutrophilic Dermatosis Induced by Ibrutinib: A Dose-Dependent Cutaneous Adverse Reaction","volume":"65","author":"Renuy","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/DAD.0000000000000980","article-title":"Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis","volume":"40","author":"Stewart","year":"2018","journal-title":"Am. J. Dermatopathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/DAD.0000000000000441","article-title":"Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal","volume":"38","author":"Mulvey","year":"2016","journal-title":"Am. J. Dermatopathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/2229-5178.93482","article-title":"Pyoderma gangrenosum: An update","volume":"3","author":"Bhat","year":"2012","journal-title":"Indian Dermatol. Online J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"710","DOI":"10.20452\/pamw.3578","article-title":"Ibrutinib-induced pyoderma gangrenosum","volume":"126","author":"Sobjanek","year":"2016","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40257-018-0356-7","article-title":"Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis","volume":"19","author":"Kridin","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/DAD.0000000000001391","article-title":"Ibrutinib and Pyoderma Gangrenosum in a Patient with B-Cell Chronic Lymphocytic Leukemia","volume":"42","author":"Giovanni","year":"2020","journal-title":"Am. J. Dermatopathol."},{"key":"ref_68","first-page":"e1","article-title":"Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports","volume":"33","author":"Gheymati","year":"2021","journal-title":"Anti-Cancer Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/0022-3859.118059","article-title":"Imatinib induced pyoderma gangrenosum","volume":"59","author":"Pinato","year":"2013","journal-title":"J. Postgrad. Med."},{"key":"ref_70","first-page":"e82952","article-title":"Ibrutinib-Induced Perianal Rash Complicated by Bacterial Infection in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review","volume":"17","author":"Singh","year":"2025","journal-title":"Cureus"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000510768","article-title":"Current Treatment of Refractory\/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs","volume":"144","author":"Smolewski","year":"2021","journal-title":"Acta Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4085\/1062-6050-0142.22","article-title":"The Identification and Treatment of Common Skin Infections","volume":"58","author":"Anderson","year":"2023","journal-title":"J. Athl. Train."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1078155219856422","article-title":"Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia\u2014Case report and literature review","volume":"26","author":"Ghasoub","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/s41375-019-0481-1","article-title":"Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies","volume":"33","author":"Rogers","year":"2019","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"ofy168","DOI":"10.1093\/ofid\/ofy168","article-title":"Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection","volume":"5","author":"Dousa","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14740\/wjon1099w","article-title":"Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib","volume":"9","author":"Stein","year":"2018","journal-title":"World J. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"New Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Barat\u00e8, C., Scortechini, I., Ciofini, S., Picardi, P., Angeletti, I., Loscocco, F., Sanna, A., Isidori, A., and Sportoletti, P. (2024). Management of infections for patient treated with ibrutinib in clinical practice. Front Oncol., 14.","DOI":"10.3389\/fonc.2024.1428464"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.15620","article-title":"Dose-limiting stomatitis associated with ibrutinib therapy: A case series","volume":"185","author":"Vigarios","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"104445","DOI":"10.1016\/j.oraloncology.2019.104445","article-title":"Ibrutinib-associated oral ulcers","volume":"100","author":"Thermos","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_87","first-page":"57","article-title":"The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies","volume":"72","author":"Elad","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2016.0225","article-title":"Hair and Nail Changes During Long-term Therapy with Ibrutinib for Chronic Lymphocytic Leukemia","volume":"152","author":"Bitar","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40800-017-0060-1","article-title":"Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review","volume":"4","author":"Manica","year":"2017","journal-title":"Drug Saf.\u2014Case Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2004.09.002","article-title":"Brittle nail syndrome: A pathogenesis-based approach with a proposed grading system","volume":"53","author":"Pasch","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_91","first-page":"e32943","article-title":"Ibrutinib-Induced Paronychia and Periungual Pyogenic Granuloma","volume":"14","author":"Alamri","year":"2022","journal-title":"Cureus"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.abd.2022.10.005","article-title":"Scanning electron microscopy of ibrutinib-induced hair shaft changes","volume":"98","author":"Sartori","year":"2023","journal-title":"An. Bras. Dermatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/371\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T11:26:43Z","timestamp":1769426803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":93,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18030371"],"URL":"https:\/\/doi.org\/10.3390\/cancers18030371","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]}}}